CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Glatiramer acetate

Last Updated: December 14, 2016
Result type: Reports
Project Number: SE0510-000
Product Line: Reimbursement Review

Generic Name: Glatiramer acetate

Brand Name: Glatect

Manufacturer: Pendopharm

Therapeutic Area: Relapsing Remitting Multiple Sclerosis (RRMS)

Indications: Multiple Sclerosis, relapsing - remitting

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 25, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions